The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures

Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventiona...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular diabetology Jg. 23; H. 1; S. 32 - 4
Hauptverfasser: Alkhami, Fadi, Borderie, Gauthier, Foussard, Ninon, Larroumet, Alice, Blanco, Laurence, Barbet-Massin, Marie-Amélie, Ferriere, Amandine, Ducos, Claire, Mohammedi, Kamel, Fawaz, Sami, Couffinhal, Thierry, Rigalleau, Vincent
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 13.01.2024
Springer Nature B.V
BMC
Schlagworte:
ISSN:1475-2840, 1475-2840
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
AbstractList Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05-4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05-4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
Abstract Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants from the general population (Rotterdam study), with a particularly close relationship for the 413 subjects with diabetes. Because conventional vascular risk factors do not capture the risk in diabetes very well, this relationship may help to select high-risk individuals for the screening of silent myocardial ischemia, which has yet to prove its benefit in randomized controlled trials. Among 477 patients with uncontrolled and/or complicated Type 2 Diabetes, we measured the SAF ten years ago, and we registered new revascularizations during a 54-months follow-up. The patients with SAF > 2.6 Arbitrary units (AUs), the median population value, experienced more revascularizations of the coronary (17/24) and lower-limb arteries (13/17) than patients with a lower SAF, adjusted for age, sex, diabetes duration, vascular complications, and smoking habits: HR 2.17 (95% CI: 1.05–4.48), p = 0.035. The SAF has already been reported to predict cardiovascular events in three cohorts of people with diabetes. We suggest that its measurement may help to improve the performance of the screening before vascular explorations and revascularizations.
ArticleNumber 32
Author Alkhami, Fadi
Larroumet, Alice
Ferriere, Amandine
Borderie, Gauthier
Foussard, Ninon
Fawaz, Sami
Blanco, Laurence
Ducos, Claire
Mohammedi, Kamel
Couffinhal, Thierry
Barbet-Massin, Marie-Amélie
Rigalleau, Vincent
Author_xml – sequence: 1
  givenname: Fadi
  surname: Alkhami
  fullname: Alkhami, Fadi
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 2
  givenname: Gauthier
  surname: Borderie
  fullname: Borderie, Gauthier
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 3
  givenname: Ninon
  surname: Foussard
  fullname: Foussard, Ninon
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 4
  givenname: Alice
  surname: Larroumet
  fullname: Larroumet, Alice
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 5
  givenname: Laurence
  surname: Blanco
  fullname: Blanco, Laurence
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 6
  givenname: Marie-Amélie
  surname: Barbet-Massin
  fullname: Barbet-Massin, Marie-Amélie
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 7
  givenname: Amandine
  surname: Ferriere
  fullname: Ferriere, Amandine
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 8
  givenname: Claire
  surname: Ducos
  fullname: Ducos, Claire
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 9
  givenname: Kamel
  surname: Mohammedi
  fullname: Mohammedi, Kamel
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 10
  givenname: Sami
  surname: Fawaz
  fullname: Fawaz, Sami
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 11
  givenname: Thierry
  surname: Couffinhal
  fullname: Couffinhal, Thierry
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University
– sequence: 12
  givenname: Vincent
  surname: Rigalleau
  fullname: Rigalleau, Vincent
  email: vincent.rigalleau@chu-bordeaux.fr
  organization: Endocrinology-Diabetology-Nutrition and Cardiology, Bordeaux CHU and University, Endocrinology-Nutrition, CHU Bordeaux, Hospital Haut-Lévêque
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38218857$$D View this record in MEDLINE/PubMed
https://hal.science/hal-04424606$$DView record in HAL
BookMark eNp9kktv1DAQxyNURB_wBTggS1zgEIgf8TrHqgJaaSUuy9nyY7LrJWsvttNqufLFcTYtjx56sDwa_f7_GY_nvDrxwUNVvcbNB4wF_5gw6SitG8LKwQTX7bPqDLNFWxPBmpN_4tPqPKVt0-CF4PhFdUoFwUK0i7Pq12oDKH13Hqkxh34YQ4RkwBtAO3VAGxj2KAeUYACT0V5lBz4ndOfyBq0Oe0AEWac0ZEjIKG-dVVPYh4iSiQDe-fVkEOFWJTMOKrqfxSR4tI_BgB1LuZfV814NCV7d3xfVt8-fVlfX9fLrl5ury2VtWsFzrSlbqE5YrqxedLwxFIjBtteK04YrTHUrdE8tKM4Np6ztCNjO2A5AC8M5vahuZl8b1Fbuo9upeJBBOXlMhLiWKmZnBpAWhOo00cIKwazRqmGm5aQ3VjPSalG83s9eGzX8Z3V9uZRTrmGMMN7wW1zYdzNbnvxjhJTlzpUZD4PyEMYkSYeLaYtpW9C3j9BtGKMvU5kpwUhHCvXmnhr1Duyf-g_fWgAxAyaGlCL00rh8HHuOyg0SN3LaIDlvkCwbJI8bJKcOyCPpg_uTIjqLUoH9GuLftp9Q_QbBJtnP
CitedBy_id crossref_primary_10_3390_biomedicines12040890
crossref_primary_10_3390_ijms26073022
crossref_primary_10_1016_j_diabet_2024_101600
crossref_primary_10_3390_ijms25073889
Cites_doi 10.1186/s12933-023-01953-x
10.1186/s12933-021-01253-2
10.1097/MD.0000000000031758
10.1136/bmj.f1654
10.1186/s12933-023-02052-7
10.2337/dc11-1333
10.1016/j.acvd.2020.07.003
10.1016/j.atherosclerosis.2022.02.014
10.1007/s00125-009-1308-9
10.1186/s12902-020-00676-4
10.1016/j.jdiacomp.2023.108595
10.1016/j.jdiacomp.2022.108206
10.1016/j.jdiacomp.2021.108015
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
licence_http://creativecommons.org/publicdomain/zero
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: licence_http://creativecommons.org/publicdomain/zero
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
1XC
VOOES
DOA
DOI 10.1186/s12933-024-02121-5
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

CrossRef
MEDLINE - Academic
MEDLINE


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1475-2840
EndPage 4
ExternalDocumentID oai_doaj_org_article_de8a9b2b8d884dcba04c562fcdb425b8
oai:HAL:hal-04424606v1
38218857
10_1186_s12933_024_02121_5
Genre Letter
Comment
Research Support, Non-U.S. Gov't
GroupedDBID ---
0R~
29B
2WC
53G
5GY
5VS
6J9
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
AFFHD
CITATION
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
ALIPV
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
1XC
VOOES
ID FETCH-LOGICAL-c586t-b347a98d6adb7960c3e2c1dfba6306a13b58bf3dea66c634592ed9cd9eeb8c663
IEDL.DBID 7X7
ISICitedReferencesCount 4
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001142867000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1475-2840
IngestDate Fri Oct 03 12:52:55 EDT 2025
Tue Dec 02 06:20:54 EST 2025
Sun Nov 09 11:43:06 EST 2025
Sat Oct 11 13:41:04 EDT 2025
Wed Feb 19 02:09:06 EST 2025
Sat Nov 29 06:27:48 EST 2025
Tue Nov 18 21:32:19 EST 2025
Sat Sep 06 07:29:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Skin autofluorescence
Type 2 diabetes
Advanced glycation end-products
Revascularization
Advanced
Humans
Risk Factors
Type 2
Skin
Diabetes Mellitus
Glycation End Products
Smoking
Language English
License 2024. The Author(s).
licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c586t-b347a98d6adb7960c3e2c1dfba6306a13b58bf3dea66c634592ed9cd9eeb8c663
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Correspondence-1
ObjectType-Commentary-3
content type line 23
ORCID 0000-0001-6139-1197
0000-0002-5175-6479
OpenAccessLink https://www.proquest.com/docview/2914284292?pq-origsite=%requestingapplication%
PMID 38218857
PQID 2914284292
PQPubID 42570
PageCount 4
ParticipantIDs doaj_primary_oai_doaj_org_article_de8a9b2b8d884dcba04c562fcdb425b8
hal_primary_oai_HAL_hal_04424606v1
proquest_miscellaneous_2914255135
proquest_journals_2914284292
pubmed_primary_38218857
crossref_citationtrail_10_1186_s12933_024_02121_5
crossref_primary_10_1186_s12933_024_02121_5
springer_journals_10_1186_s12933_024_02121_5
PublicationCentury 2000
PublicationDate 2024-01-13
PublicationDateYYYYMMDD 2024-01-13
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-13
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Cardiovascular diabetology
PublicationTitleAbbrev Cardiovasc Diabetol
PublicationTitleAlternate Cardiovasc Diabetol
PublicationYear 2024
Publisher BioMed Central
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: Springer Nature B.V
– name: BMC
References HL Kim (2121_CR3) 2022; 101
T Hirai (2121_CR11) 2023; 22
M Yoshida (2121_CR2) 2012; 35
G Borderie (2121_CR7) 2023; 37
HE Boersma (2121_CR10) 2021; 21
Q Jin (2121_CR9) 2021; 35
K Mohammedi (2121_CR6) 2021; 20
J Pan (2121_CR12) 2022; 345
CK Kramer (2121_CR4) 2013; 25
HL Lutgers (2121_CR8) 2009; 52
P Valensi (2121_CR5) 2021; 114
J Škrha Jr (2121_CR13) 2022; 36
J Chen (2121_CR1) 2023; 22
38017418 - Cardiovasc Diabetol. 2023 Nov 28;22(1):326
References_xml – volume: 22
  start-page: 213
  issue: 1
  year: 2023
  ident: 2121_CR11
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-023-01953-x
– volume: 20
  start-page: 63
  issue: 1
  year: 2021
  ident: 2121_CR6
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-021-01253-2
– volume: 101
  issue: 45
  year: 2022
  ident: 2121_CR3
  publication-title: Medicine (Baltimore)
  doi: 10.1097/MD.0000000000031758
– volume: 25
  issue: 346
  year: 2013
  ident: 2121_CR4
  publication-title: BMJ
  doi: 10.1136/bmj.f1654
– volume: 22
  start-page: 326
  issue: 1
  year: 2023
  ident: 2121_CR1
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-023-02052-7
– volume: 35
  start-page: 178
  issue: 1
  year: 2012
  ident: 2121_CR2
  publication-title: Diabetes Care
  doi: 10.2337/dc11-1333
– volume: 114
  start-page: 150
  issue: 2
  year: 2021
  ident: 2121_CR5
  publication-title: Arch Cardiovasc Dis
  doi: 10.1016/j.acvd.2020.07.003
– volume: 345
  start-page: 26
  year: 2022
  ident: 2121_CR12
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2022.02.014
– volume: 52
  start-page: 789
  issue: 5
  year: 2009
  ident: 2121_CR8
  publication-title: Diabetologia
  doi: 10.1007/s00125-009-1308-9
– volume: 21
  start-page: 14
  issue: 1
  year: 2021
  ident: 2121_CR10
  publication-title: BMC Endocr Disord
  doi: 10.1186/s12902-020-00676-4
– volume: 37
  issue: 10
  year: 2023
  ident: 2121_CR7
  publication-title: J Diabetes Complications
  doi: 10.1016/j.jdiacomp.2023.108595
– volume: 36
  issue: 7
  year: 2022
  ident: 2121_CR13
  publication-title: J Diabetes Complications
  doi: 10.1016/j.jdiacomp.2022.108206
– volume: 35
  issue: 10
  year: 2021
  ident: 2121_CR9
  publication-title: J Diabetes Complications
  doi: 10.1016/j.jdiacomp.2021.108015
– reference: 38017418 - Cardiovasc Diabetol. 2023 Nov 28;22(1):326
SSID ssj0017861
Score 2.3801653
Snippet Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001 participants...
Abstract Chen et al. recently related the skin autofluorescence (SAF) of Advanced Glycation End-products to subclinical cardiovascular disease in the 3001...
SourceID doaj
hal
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 32
SubjectTerms Advanced glycation end-products
Advanced glycosylation end products
Angiology
Arteries
Atherosclerosis
Cardiology
Cardiovascular disease
Cardiovascular diseases
Carotid arteries
Clinical trials
Cohort analysis
Comment
Coronary vessels
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - diagnosis
Foot diseases
Glycation End Products, Advanced
Health risks
Human health and pathology
Humans
Ischemia
Leg ulcers
Life Sciences
Medical prognosis
Medicine
Medicine & Public Health
Mortality
Myocardial ischemia
Population studies
Revascularization
Risk Factors
Skin
Skin autofluorescence
Smoking
Type 2 diabetes
Vein & artery diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQhRAXBGULlMogbhA1i-PlWBBVD23FAVBvlreoFa9J9ZJU4swfZ8ZxHlQVcOktcrzP2DPjsb8h5K1oC-Fqhm51sHRgl7S5MQy-XC2kKlljI5D2tyNxciJPT9XnP0J94Z2wGR54nrg9H6RRtrLSS8m8s6ZgDmR267wFdrPxmW8h1GJMJf-BkLxcnshIvjegVEN_JcsR0rzMm2tiKKL1g3A5w7uQNxXNG07SKHsOHpIHSWmk-3NnH5E7odsm946TW_wx-QnEpsP3846aaezb1dSvI0qTC_TC_KBnYXVJx54OMeYNTVCqA8UzWIqGKK3ocgZLHb5zwWOAgYI-S2FXAUsXeoUVrMNycTW93qRR_vkJmntCvh58-vLxME_RFXLXSD7mtmbCKOm58VaAHePqULnSt9ZwMCMMUK2Rtq19MJw7XrNGVcEr51UIVjpQVJ6Sra7vwnNCoWxReOMY3lN0pjDWS2sNfFbOWFVmpFwmW7sEPY4RMFY6miCS65lAGgikI4F0k5F3mzKXM_DGP3N_QBpuciJodkwAVtKJlfT_WCkjb4ADrtVxuH-kMa1grGJg613BWHYWBtFpuQ-6Ughch5G_MvJ68xsWKnpfTBf6KeXBcDrQ2WczY22aqiVoWrIRGXm_cNrvyv8-6he3MeqX5H4VF0aZl_UO2RrXU3hF7rqr8XxY78Zl9QuUPSZo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: SpringerLink Journals
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwELagINQLOyVQkEHcIGoWx7GPBVH1UCrEUvVmeQuteCRVlkqc-ePM-DlBVQEJbpHj3eNZPPY3hLyom6y2JUO3Olg6wCVNqjWDL1vWQuasMgFI--igPjwUx8fyfXwUNsy33WeXZODUYVsLvjOgZEKfI0sRljxPq6vkGog7gQEbPnw8WnwHteD5_Dzmt-UuiKCA1A-C5QTvQV5WMi85SIPc2bv1fz2-TW5GPZPurgnjDrni27vkxrvoSb9HfgB90OHraUv1NHbNaur6AOxkPf2mv9MTvzqjY0eHECaHRvTVgeKxLUXblRZ0PralFp_G4MnBQEEFpsCIwDiGjmIFvZ_vusYHnzSITDdBc_fJ5723n97spzEgQ2orwcfUlKzWUjiunanB9LGlL2zuGqM5WB4aFroSpimd15xbXrJKFt5J66T3RljQbR6QjbZr_UNCoWyWOW0ZXm20OtPGCWM0fBZWG5knJJ_XSNmIVo5BM1YqWC2Cq_XsKphdFWZXVQl5uZQ5W2N1_DX3a1z6JSfibIeErv-i4rZVzgstTWGEE4I5a3TGLGiMjXUGmJ0RCXkOhHOhjv3dA4VpGWMFA_PwHMayPdOVihxiUIVErDsMFpaQZ8tv2NvosNGt76aYByPwQGe31vS4NFUKUM5EVSfk1Ux8vyr_86gf_Vv2x2SzCPSbp3m5TTbGfvJPyHV7Pp4O_dOw734CmWEo1g
  priority: 102
  providerName: Springer Nature
Title The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures
URI https://link.springer.com/article/10.1186/s12933-024-02121-5
https://www.ncbi.nlm.nih.gov/pubmed/38218857
https://www.proquest.com/docview/2914284292
https://www.proquest.com/docview/2914255135
https://hal.science/hal-04424606
https://doaj.org/article/de8a9b2b8d884dcba04c562fcdb425b8
Volume 23
WOSCitedRecordID wos001142867000005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: RBZ
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: DOA
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: M~E
  dateStart: 20020101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Health & Medical Collection (ProQuest)
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1475-2840
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017861
  issn: 1475-2840
  databaseCode: RSV
  dateStart: 20021201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagRYgL70KgrAziBlHzcBLnhFrUqkjtalWgWk6WX6EVS7LkUYkzf5wZr7NVVdELl1WSdRxb83me9gwhb4sqKnTKMKwOlg5wSRVKyeBKpwUvY5Ypl0j79KiYTvl8Xs68w63z2ypHnugYtWk0-sh3khJzg2FxpQ_LXyFWjcLoqi-hcZtsYtlsxHkxXxtcccHzeDwow_OdDmUbRi1ZiInN4zC7Ioxczn4QMWe4I_K6unktVOok0MGD_x37Q3Lf6550dwWWR-SWrR-Tu8c-uv6E_AHM0O7HeU3l0DfVYmhal-xJW_pT_qZndrGkfUM7VzqH-oysHUVXLkV7liZ0dOVSjcdl0JvQUVCLKTAnMJhhWthBa8f9r_4QKHVi1Azwuafk68H-l4-HoS_SEOqM532oUlbIkptcGlWAOaRTm-jYVErmYI1IIH7GVZUaK_Nc5ynLysSaUpvSWsU16DtbZKNuavucUHg3iozUDLc7ahlJZbhSEi4TLVUZByQeqSW0z2COhTQWwlkyPBcrCgugsHAUFllA3q3fWa7yd9zYeg9BsG6Jubfdg6b9LvxSFsZyWapEccM5M1rJiGnQIittFDBAxQPyBiB0pY_D3SOBzyLGEgYm4wXMZXuEivBcoxOXOAnI6_XfsN4xiCNr2wy-DVblgcE-WyFz_amUg8LGsyIg70eoXnb-71m_uHksL8m9xK2ZOIzTbbLRt4N9Re7oi_68ayduxblfPiGbe_vT2cnEOTbgbvbpePYN7k4-n_4FpVI5Ew
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFH4qBVEu7EugwIDgVKx6GdvjA0JlqVI1jTgUlNswW9qKEIc4KeqZ_8Nv5L3xUlUVvfXAzbLH47H9vf3NewCv8nGYm4RTWB0tHeSSOlCK45FJclFEPNW-kPbXQT4citGo-LwCf9q9MJRW2fJEz6htachHvhkXVBuMmiu9m_0MqGsURVfbFho1LHbdyS802aq3Ox_x_76O4-1P-x_6QdNVIDCpyBaBTniuCmEzZXWO-rtJXGwiO9YqQ_VZ4WpToceJdSrLTJbwtIidLYwtnNPCoIDGea_AVVxJTsZePuoMvCgXWdRuzBHZZkWylKKkPKBC6lGQnhF-vkcAirRDysA8r96eC816ibd963_7VrfhZqNbs62aGO7Aipvehet7TfbAPfiNNMGq70dTppaLcjxZlnNfzMo49kOdsEM3mbFFySrfGog1FWcrRq5qRvY6i1nrqmaGtgORt6RiqPYzZL7OkYuJJpi7Nr-32eTKvJpgl_i4-_DlUj7BA1idllP3CBjeG4ZWGU7pnEaFSluhtcLD2ChdRD2IWnRI01Rop0YhE-ktNZHJGlESESU9omTag43unlldn-TC0e8JdN1Iqi3uT5TzA9mwKmmdUIWOtbBCcGu0CrlBLXlsrEYGr0UPXiJkz8zR3xpIOhdyHnM0iY_xXdZbaMqGK1byFJc9eNFdRn5GQSo1deWyGUNdh3CxD2tK6B6VCFRIRZr34E1LGqeT__utH1-8luew1t_fG8jBznD3CdyIPb1GQZSsw-pivnRP4Zo5XhxV82ee2hl8u2yS-QtW-5J2
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9UwELagoIoL-xIoYBA3iJrFSexjWZ6KeDxVAqreLG-hFY_kKUslzvxxZpwFqgIS4mYl3uKMPTOemW8IeVaUUWFShmZ10HTglNShUgxKJi24iFmmPZD24bJYrfjRkTj4JYrfe7tPJskhpgFRmqpud2PLYYvzfLdFLoX2RxYiRHkcZhfJJYaO9Kivfzic7QgFz-MpVOa37c6wI4_aD0zmGH0izwuc54ylngctrv3_7K-Tq6P8SfcGgrlBLrjqJtl-P1rYb5HvQDe0_XJSUdV3dbnu68YDPhlHv6pv9NitN7SraevT59ARlbWleJ1LUaelCZ2uc6nBkBm8UWgpiMYUDihQmmHS2EHjJh_YMRCUelZqexjuNvm0ePPx1X44JmoITcbzLtQpK5TgNldWF6ASmdQlJralVjloJAoIIOO6TK1TeW7ylGUicVYYK5zT3IDMc4dsVXXl7hEKbaPIKsPQ5dGoSGnLtVZQTIzSIg5IPP0vaUYUc0ymsZZem-G5HFZXwupKv7oyC8jzuc1mwPD4a-2XSAZzTcTf9g_q5rMct7O0jiuhE80t58warSJmQJIsjdVwCGoekKdARGf62N9bSnwWMZYwUBtP4Vt2JhqT48nRykQgBh4mEQvIk_k17Hk05KjK1f1YBzPzwGTvDrQ5D5VyENp4VgTkxUSIPzv_81ff_7fqj8n2weuFXL5dvXtAriSelOMwTnfIVtf07iG5bE67k7Z55LfjD4iTNJ4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+skin+autofluorescence+may+help+to+select+patients+with+Type+2+diabetes+candidates+for+screening+to+revascularization+procedures&rft.jtitle=Cardiovascular+diabetology&rft.au=Alkhami%2C+Fadi&rft.au=Gauthier+Borderie&rft.au=Foussard%2C+Ninon&rft.au=Larroumet%2C+Alice&rft.date=2024-01-13&rft.pub=Springer+Nature+B.V&rft.eissn=1475-2840&rft.volume=23&rft.spage=1&rft_id=info:doi/10.1186%2Fs12933-024-02121-5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2840&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2840&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2840&client=summon